Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Michigan for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Michigan only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Michigan (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Amar Majjhoo (NPI 1255411039)

Field	Value
Entity Type	Individual
Organization	Amar Majjhoo
Address	29200 Harper Ave
City	Saint Clair Shores
State	MI
ZIP	48081
Taxonomy	Rheumatology Physician
NPI Enumerated	October 16, 2006

Payer Source	Total Paid
Medicare	$1.6M
Medicaid	$0

Key Findings

AMAR MAJJHOO is a Rheumatology Physician with Total Medicare revenue of $1.6M and no Medicaid billing on file, making the practice effectively single‑payer Medicare in scale. The NPI was enumerated on 2006-10-16 (~20 years ago), indicating an established practice tenure with nearly two decades of enrollment activity.

Revenue is highly concentrated in a small set of biologic infusion/drug codes: the precomputed top 3 codes by revenue account for 76.4% of this provider's total Medicare revenue. Those top contributors are J3262 ($477.2K, 28.8%), J0129 ($441.2K, 26.6%), and J1602 ($348.7K, 21.0%), which together dominate the Medicare top-line for this provider.

The procedure mix points to an infusion‑centric, specialty drug business model: large volumes of J3262 (tocilizumab), J0129 (abatacept), and J1602 (golimumab) indicate routine administration of physician‑supervised biologic therapies in‑office or in an infusion suite. The presence of J0717 (certolizumab pegol) and J0897 (denosumab) further supports a practice delivering multiple infused or injected specialty agents rather than relying primarily on office evaluation visits.

Competitive standing on core biologics is modest-to-strong but not dominant: J3262 ranks #56 of 618 providers nationally (91th percentile; typical, unremarkable volume), J1602 ranks #142 of 1041 (86th percentile; typical, unremarkable volume), and J0129 ranks #307 of 1221 (75th percentile; typical, unremarkable volume). These ranks imply the provider is a higher-volume user of certain biologics relative to many peers, yet the activity falls within the data set’s labeled “typical” range rather than qualifying as a national outlier or clear market leader.

There is a notable statistical outlier in chemotherapy/infusion administration: 96413 generated $65.1K (3.9% of Medicare revenue) from 614 claims and ranks #396 of 7514 providers nationally (95th percentile; notably above typical national volume). This suggests unusually high utilization of that specific chemotherapy/infusion administration code compared with national peers, which may reflect sustained infusion throughput or broader infusion services beyond routine rheumatology biologics.

Evaluation-and-management activity is a small share of billed Medicare revenue relative to drug administration: 99214 produced $43.7K (2.6%) from 470 claims (rank #54096 of 479517, 89th percentile; typical) while 99213 produced $4.2K (0.3%) from 59 claims. The relatively low revenue share from E/M codes indicates the practice’s financial model is driven more by drug/infusion billing than by standard outpatient visit volume.

The code mix includes secondary infusion and procedural codes that imply operational capability for varied infusion encounters and procedures: 96401 (203 claims, $12K, 0.7%), 96415 (90 claims, $2.1K, 0.1%), and 20610 (62 claims, $3.8K, 0.2%) are present on the file. These entries point to the practice performing both subcutaneous/intramuscular administrations and extended infusion sessions plus occasional joint procedures, which aligns with a clinic equipped for onsite drug delivery and minor musculoskeletal interventions.

The absence of any Medicaid billing on file means payer diversification is limited; the provider’s revenue exposure is concentrated in Medicare reimbursement patterns and specialty drug utilization. For payers and risk analysts, this profile signals sensitivity to Medicare pricing, coverage decisions for infused biologics, and changes in utilization of high-revenue J‑codes that together would materially affect the practice’s revenue base.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

14 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J3262	Injection, tocilizumab, 1 mg	95,440	$10	$477.2K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	12,980	$30	$441.2K
J1602	Injection, golimumab, 1 mg, for intravenous use	31,700	$10	$348.7K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	51,000	$1	$204K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	610	$110	$65.1K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	470	$90	$43.7K
J0897	Injection, denosumab, 1 mg	2,400	$20	$43.2K
99204	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider…	110	$120	$13.1K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	200	$60	$12K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	60	$70	$4.2K

Showing 1–10 of 14

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 14 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Michigan Distribution

Amar Majjhoo — 3 of 14 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Michigan

Full comparison — all codes billed, vs. state median

14 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	2	20	7,700	$30	$285.5K
J3262	2	10	26,240	$1	$191.1K
J0717	2	10	49,600	$1	$155.2K
J1602	1	20	14,430	$10	$153.5K
J0897	87	170	2,460	$20	$69.1K
96413	2	170	120	$100	$16.1K
99214	877	15,470	80	$80	$11.4K
99213	7,631	14,810	60	$60	$6.6K
96401	8	80	90	$50	$5.8K
99204	297	6,280	30	$110	$4.2K

Showing 1–10 of 14

Related Providers

Other providers that share a Tax Identification Number (TIN) with Amar Majjhoo, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Andrew Sulich	MI	Rheumatology Physician	$1.7M	$0

Nearby Providers

Other providers in the same ZIP code as Amar Majjhoo, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Home Life Styles Inc	MI	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$10.9M
Alliance Physician Services Of Michigan, P.C.	MI	Urology Physician	$0	$8.9M
City Of St. Clair Shores	MI	Land Ambulance	$448.5K	$1M
Rima Tinawi-aljundi	MI	Anatomic Pathology Physician	$766.3K	$0
Eastside Associates, LLC	MI	Endoscopy Clinic/Center	$677.6K	$2.9K
Juan Frontera	MI	Urology Physician	$432.4K	$0
Shiva Maralani	MI	Urology Physician	$367.9K	$0
Michael Clune	MI	Ophthalmology Physician	$364.7K	$0
Scott Wilkinson	MI	Urology Physician	$349.2K	$0
Richard Cross	MI	Nephrology Physician	$296.6K	$0

Amar Majjhoo — Billing Profile & Reimbursement Data

Sign up for Amar Majjhoo — Billing Profile & Reimbursement Data policy alerts

Amar Majjhoo — Billing Profile & Reimbursement Data

Sign up for Amar Majjhoo — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References